Health Law Daily Wrap Up, CONTROLLED SUBSTANCES—FINAL RULES: DEA moves to ban four emerging synthetic opioids, (Aug 31, 2026)

By WK Editorial Staff

The DEA said the four synthetic opioids will be subject to Schedule I controls because evidence of trafficking, polysubstance use, overdoses, and fatalities indicates they present significant risks to public health and safety.

The DEA announced a temporary order placing four synthetic opioids, 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine, into Schedule I of the Controlled Substances Act because they pose an imminent hazard to public safety. The agency found that these substances have been identified in drug seizures, toxicology reports, and overdose investigations, and are pharmacologically similar to other highly potent opioids, including fentanyl and brorphine. DEA cited evidence that the drugs are increasingly present in the illicit market, are often combined with other substances, and have been linked to overdose deaths and other serious health risks. Effective August 27, 2026, the temporary scheduling order subjects the substances to the regulatory controls and criminal, civil, and administrative sanctions applicable to Schedule I controlled substances and will remain in effect for two years, with the possibility of a one-year extension (Final Rule, 91 Fed. Reg. 55252 (Aug. 27, 2026)).

Dates. This temporary order is effective August 27, 2026, until August 27, 2028. If this order is extended or made permanent, DEA will publish a document in the Federal Register.

FederalRegisterIssuances: FinalRules ControlledNews DrugBiologicNews